As per Attached Document.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sanjivani Paranteral Ltd reported standalone revenue of ₹1,380.91 lakh in Q4 FY2026 and ₹6,975.64 lakh for the full year, down from ₹7,131.21 lakh in FY2025. Profit after tax stood at ₹54.85 lakh for Q4 and ₹669.38 lakh for the full year, compared to ₹809.43 lakh in the prior year. EPS for FY2026 was ₹5.49 versus ₹6.89 in FY2025. The company cited temporary disruptions in pharmaceutical markets during Q4 causing production challenges and a write-off of ₹6 crore worth of inventory, impacting margins. However, it highlighted a 242 basis point improvement in operational efficiency through cost reduction. The Pune IV Fluids plant is scaling well with growing traction, and a WHO-GMP approved facility has received export authorization, opening overseas markets.
The full-year revenue and profit declined year-over-year due to one-time disruptions in Q4, though management attributes these to temporary factors. Shareholders should monitor whether the Pune facility ramp-up and new export orders offset the ongoing margin pressure in FY2027.